Thyroid disease

Primary Care - Clinics in Office Practice

Volumn 30, Issue 4, 2003, Pages 625-640

  Evans, Timothy C ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b GIMC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; THYROTROPIN;

CANCER SCREENING; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FOLLOW UP; GENERAL PRACTICE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MEDICAL PRACTICE; PATIENT SELECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SYMPTOM; THYROID CANCER; THYROID DISEASE; TITRIMETRY; TREATMENT INDICATION;

EID: 0346433972     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00087-3     Document Type: Review

References (100)

1. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000;160(11):1573-6.
2. De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. Br J Gen Pract 1995;45(391):93-5.
3. Parle JV, Franklyn JA, Cross KW, et al. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract 1993;43(368):107-9.
4. Wiersinga WM. Thyroid hormone replacement therapy. Horm Res 2001;56(Suppl 1): 74-81.
5. Woeber KA. Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations. J Endocrinol Invest 2002;25(2):106-9.
6. Escobar-Morreale HF, del Rey FE, Obregon MJ, et al. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology 1996;137(6):2490-502.
7. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61(Suppl 1):26-32.
8. Jackson IM. The thyroid axis and depression. Thyroid 1998;8(10):951-6.
9. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50(5):387-93.
10. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32(3):241-51.
11. Lasser RA, Baldessarini RJ. Thyroid hormones in depressive disorders: a reappraisal of clinical utility. Harv Rev Psychiatry 1997;4(6):291-305.
12. Marangell LB. Augmentation of standard depression therapy. Clin Ther 2000;22(Suppl A):A25-38 [discussion A39-41].
13. Bunevicius R, Kazanavicius G, Zalinkevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999;340(6):424-9.
14. Bunevicius R, Prange AJ. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol 2000;3(2):167-74.
15. Duntas LH. Thyroid disease and lipids. Thyroid 2002;12(4):28-93.
16. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S109-12.
17. Vlase H, Lungu G, Vlase L. Cardiac disturbances in thyrotoxicosis: diagnosis, incidence, clinical features and management. Endocrinologie 1991;29(3-4):155-60.
18. Chen YC, Chen SA, Chen YJ, et al. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol 2002;39(2):366-72.
19. Komiya N, Isomoto S, Nakao K, et al. Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism. Clin Endocrinol (Oxf) 2002;56(1):39-44.
20. Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997;47(418):285-9.
21. Kerr CR, Boone J, Connolly SJ, et al. The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. Am J Cardiol 1998;82(8A):82N-5N.
22. Lok NS, Lau CP. Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. Int J Cardiol 1995;48(3):271-8.
23. Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 1996;17(Suppl C):48-51.
24. Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996;44(1):50-3.
25. Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust 1996;164(4):200-3.
26. Peters A, Ehlers M, Blank B, et al. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 2000;160(13):1993-9.
27. Locker GJ, Kotzmann H, Frey B, et al. Factitious hyperthyroidism causing acute myocardial infarction. Thyroid 1995;5(6):465-7.
28. Gennari C, Martini G, Nuti R. Secondary osteoporosis. Aging (Milano) 1998;10(3): 214-4.
29. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000;11(8):637-59.
30. Loviselli A, Mastinu R, Rizzolo E, et al. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 1997;7(4):561-6.
31. Taimela E, Taimela S, Nikkanen V, et al. Accelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxyterminal telopeptide region of type I collagen in serum. Eur J Clin Chem Clin Biochem 1994;32(11):827-31.
32. Toivonen J, Tahtela R, Laitinen K, et al. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 1998;138(6):667-73.
33. Adlin EV, Maurer AH, Marks AD, et al. Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med 1991;90(3):360-6.
34. Gomez Acotto C, Schott AM, Hans D, et al. Hyperthyroidism influences ultrasound bone measurement on the Os calcis. Osteoporos Int 1998;8(5):455-9.
35. Hadji P, Hars O, Sturm G, et al. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol 2000;142(5):445-50.
36. Sijanovic S, Karner I. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. Medscape Womens Health 2001;6(5):3.
37. Stall GM, Harris S, Sokoll LJ, et al. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990;113(4):265-9.
38. Baldini M, Gallazzi M, Orsatti A, et al. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med 2002;251(5):407-14.
39. Fujiyama K, Kiriyama T, Ito M, et al. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid 1995;5(1):13-7.
40. Gyulai L, Bauer M, Garcia-Espana F, et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001;66(2-3):185-91.
41. Nuzzo V, Lupoli G, Esposito Del Puente A, et al. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. Gynecol Endocrinol 1998;12(5):333-7.
42. Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996;81(3):1232-6.
43. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999;130(9):750-8.
44. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81(12):4278-89.
45. Lupoli G, Nuzzo V, Di Carlo C, et al. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol 1996;10(5):343-8.
46. Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998;83(7):2324-30.
47. Cooper DS. Subclinical hyperthyroidism. N Engl J Med 2001;345(4):260-5.
48. Kong WM, Sheikh MH, Lumb PJ, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 2002;112(5): 348-54.
49. Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med 1985;145(8):1386-8.
50. Rivolta G, Cerutti R, Colombo R, et al. Prevalence of subclinical hypothyroidism in a population living in the Milan metropolitan area. J Endocrinol Invest 1999;22(9): 693-7.
51. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43(1):55-68.
52. Moore DC. Natural course of 'subclinical' hypothyroidism in childhood and adolescence. Arch Pediatr Adolesc Med 1996;150(3):293-7.
53. Rubello D, Pozzan GB, Casara D, et al. Natural course of subclinical hypothyroidism in Down's syndrome: prospective study results and therapeutic considerations. J Endocrinol Invest 1995;18(1):35-40.
54. Wiersinga WM. Subclinical hypothyroidism and hyperthyroidism. I. Prevalence and clinical relevance. Neth J Med 1995;46(4):197-204.
55. Kabadi UM. 'Subclinical hypothyroidism'. Natural course of the syndrome during a prolonged follow-up study. Arch Intern Med 1993;153(8):957-61.
56. Kabadi UM, Cech R. Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat. J Endocrinol Invest 1997;20(6):319-26.
57. Bona M, Santini F, Rivolta G, et al. Cost effectiveness of screening for subclinical hypothyroidism in the elderly. A decision-analytical model. Pharmacoeconomics 1998;14(2):209-16.
58. Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996;11(12):744-9.
59. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000;10(8):665-79.
60. Tagliaferri M, Berselli ME, Calo G, et al. Subclinical hypothyroidism in obese patients: relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res 2001;9(3):196-201.
61. Tzotzas T, Krassas GE, Konstantinidis T, et al. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000;10(9):803-8.
62. Vierhapper H, Nardi A, Grosser P, et al. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid 2000;10(11):981-4.
63. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992;92(6):631-42.
64. Miura S, Iitaka M, Yoshimura H, et al. Disturbed lipid metabolism in patients with subclinical hypothyroidism: effect of L-thyroxine therapy. Intern Med 1994:33(7): 413-7.
65. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hyper-cholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf) 1996;44(6):643-9.
66. Bindels AJ, Westendorp RG, Frolich M, et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Clin Endocrinol (Oxf) 1999;50(2):217-20.
67. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 1998;138(2):141-5.
68. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132(4):270-8.
69. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002;87(4):1533-8.
70. Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001;86(10): 4860-6.
71. Efstathiadou Z, Bitsis S, Milionis HJ, et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol 2001;145(6):705-10.
72. Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypotliyroidiSM. J Clin Endocrinol Metab 1999;84(6):2064-7.
73. Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab 2001;86(3):1110-5.
74. Haggerty JJ Jr, Stern RA, Mason GA, et al. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993;150(3):508-10.
75. Baldini IM, Vita A, Mauri MC, et al. Psychopathological and cognitive features in subclinical hypothyroidism. Prog Neuropsychopharmacol Biol Psychiatry 1997;21(6): 925-35.
76. Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160(4):526-34.
77. Pines A, Dotan I, Tabori U, et al. L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism. Gynecol Endocrinol 1999;13(3):196-201.
78. Campbell J, Day P, Diamond T. Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid 1996;6(2):75-8.
79. Toft AD. Subclinical hyperthyroidism. N Engl J Med 2001;345(7):512-6.
80. Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid 1996;6(5):391-6.
81. Fatourechi V. Adverse effects of subclinical hyperthyroidism. Lancet 2001;358(9285): 856-7.
82. Koutras DA. Subclinical hyperthyroidism. Thyroid 1999;9(3):311-5.
83. Marqusee E, Haden ST, Utiger RD. Subclinical thyrotoxicosis. Endocrinol Metab Clin North Am 1998;27(1):37-49.
84. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med 1990;150(4):785-7.
85. Kalmijn S, Mehta KM, Pols HA, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000;53(6):733-7.
86. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358(9285):861-5.
87. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331(19):1249-52.
88. Krahn AD, Klein GJ, Kerr CR, et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med 1996;156(19):2221-4.
89. Osman F, Gammage MD, Sheppard MC, et al. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab 2002;87(3):963-7.
90. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000;85(12):4701-5.
91. Faber J, Wiinberg N, Schifter S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 2001;145(4):391-6.
92. Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000;85(1):159-64.
93. Foldes J, Tarjan G, Szathmari M, et al. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol (Oxf) 1993;39(5):521-7.
94. Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79(1):62-9 [discussion 69-70].
95. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999;9(6): 539-43.
96. Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000;85(11):4157-61.
97. Faber J, Jensen IW, Petersen L, et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in post-menopausal women. Clin Endocrinol (Oxf) 1998;48(3):285-90.
98. Gharib H. The use of recombinant thyrotropin in patients with thyroid cancer. Endocrinologist 2000;10(4):255-63.
99. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87(4):1490-8.
100. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86(12):5686-90.